학술논문
Leukocytes telomere length as a biomarker of adverse drug reactions induced by Osimertinib in advanced non-small cell lung cancer.
Document Type
Academic Journal
Author
Trachu N; Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.; Reungwetwattana T; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.; Meanwatthana J; Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.; Sukasem C; Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.; Majam T; School of Pharmacy, Walailak University, Nakhon Si Thammarat, Thailand.; Saengsiwaritt W; Department of Biochemistry, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudthaya Road, Rajathevi, Bangkok, 10400, Thailand.; Jittikoon J; Department of Biochemistry, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudthaya Road, Rajathevi, Bangkok, 10400, Thailand.; Udomsinprasert W; Department of Biochemistry, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudthaya Road, Rajathevi, Bangkok, 10400, Thailand. wanvisa.udo@mahidol.ac.th.
Source
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
Subject
Language
English
Abstract
This study aimed to measure relative telomere length (RTL) in blood leukocytes of advanced-stage NSCLC patients either with or without Osimertinib-induced ADRs and determine whether RTL could serve as a biomarker of Osimertinib-induced ADRs. Blood leukocytes RTL were measured in 63 advanced-stage NSCLC patients and 62 age-matched healthy controls using real-time polymerase chain reaction. In patients with advanced-stage NSCLC, RTL was significantly shorter than that in healthy controls (P < 0.001). Compared to patients without ADRs and those with mild/moderate ADRs, patients with severe ADRs exhibited significantly decreased RTL (P < 0.001, P < 0.001, respectively). ROC curve analysis uncovered a diagnostic value of RTL as a biomarker of Osimertinib-induced ADRs (AUC = 1.000, P < 0.001). Kaplan-Meier analysis revealed a significant association between shorter RTL and increased cumulative incidence of Osimertinib-induced ADRs in patients with advanced-stage NSCLC (P < 0.001). Shorter RTL in blood leukocytes would reflect the occurrence of Osimertinib-induced ADRs and might emerge as a promising biomarker for identifying advanced-stage NSCLC patients who are at risk of experiencing Osimertinib-induced ADRs, particularly those with severe ADRs.
(© 2024. The Author(s).)
(© 2024. The Author(s).)